Peptide stability

Peptide stability is not a biological target, molecule, or receptor; rather, it is a critical physicochemical and pharmacokinetic property of peptide-based therapeutic agents. It refers to the ability of a peptide to maintain its structural integrity and biological activity against various degradation processes, including enzymatic proteolysis by peptidases, chemical hydrolysis, oxidation, and aggregation (Source: PubMed, PMID: 31035315). High peptide stability is essential for ensuring that a drug remains in the systemic circulation long enough to reach its intended site of action and exert a therapeutic effect. Factors influencing this property include the primary amino acid sequence, secondary structure, and the presence of specific chemical modifications like PEGylation, cyclization, or the use of D-amino acids (Source: Nature Reviews Drug Discovery). In clinical contexts, poor peptide stability often leads to low oral bioavailability and a short half-life, necessitating frequent parenteral administration. Researchers optimize this property during the lead optimization phase of drug discovery to overcome the inherent susceptibility of natural peptides to rapid clearance (Source: Journal of Medicinal Chemistry). Because it represents a characteristic of the drug molecule itself and not a physiological protein or pathway being targeted, it is classified as a pharmaceutical parameter rather than a therapeutic target.

Other names

Metabolic stabilityProteolytic stabilityChemical stabilityPeptide half-lifeSerum stability